🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TALAPRO-2: Talazoparib+Enzalutamide hits 45.1 mo OS (HR 0.62). A landmark result (Z=–3.58, SNR=3.58, p<2.6×10⁻⁹ [our calc]) But no survival analysis by prior mHSPC therapy despite its known prognostic impact. A critical blind spot. 📄 doi.org/10.1016/S0140-… #ProstatCa #PARPi

🔹FLAURA2 confirms it: Osimertinib + chemo sets a new OS record (50.0 vs 42.1 mo, HR 0.75). But does this kill sequential strategy? Not necessarily. Post-progression Amivantamab still matters perhaps even more after earlier TKI + chemo pressure. 🔗 bit.ly/FLAURA2-OS #EGFR

🔬NEW in Lancet Oncology: HER2DX risk score independently predicts survival in early HER2+ breast cancer. Across 11 studies (n=2518), HER2DX stratified long term EFS beyond stage, pCR, or HR status. 📄 doi.org/10.1016/S1470-… #BreastCancer #Oncology #HER2